
Sign up to save your podcasts
Or


On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
By Alzheimer's Association New England Region5
77 ratings
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).

21,977 Listeners

38,491 Listeners

30,713 Listeners

43,545 Listeners

27,154 Listeners

3,465 Listeners

2,637 Listeners

9,253 Listeners

8,203 Listeners

57,753 Listeners

4,496 Listeners

2,035 Listeners

10,530 Listeners

5,912 Listeners

15 Listeners